A groundbreaking global trial has delivered what researchers are calling the best results ever seen for early-stage Hodgkin lymphoma, with 96 percent of patients seeing their cancer disappear on scans and remaining disease-free after three years. The findings offer hope for a cure to the thousands of young adults diagnosed with this blood cancer each year.
The study, published in the journal Blood, involved replacing two of the four conventional chemotherapy drugs traditionally used for Hodgkin lymphoma with targeted immunotherapy drugs. Of the 154 patients who received the new combination, nearly all had their cancer vanish on scans and stayed in remission. Three young participants from Victoria, Australia, all remain cancer-free three years later. Professor H Miles Prince AM, a lead author and haematologist at Epworth HealthCare, called the results incredible. “Virtually all patients were put in remission, and with the long follow-up we have, we can be confident that they are likely cured,” he said.
One of those patients, Tomas Parrish-Chynoweth, was diagnosed at age 26 with an 11-centimetre tumour pressing against the heart and lung. After just two months on the trial, the cancer was no longer active. Tomas described the treatment as a “lifeline” compared to standard chemotherapy. Professor Prince noted the new regimen was not only more effective but also better tolerated. “Not only are these the best results ever seen for this group of patients, but it was also better tolerated than the usual chemotherapy cocktail of drugs we have had to give,” he said.
Hodgkin lymphoma is a blood cancer that grows in lymph nodes and the lymphatic system, most commonly striking people aged 15 to 39. In Australia, about 830 people are diagnosed each year, with half in that age group. The trial’s success marks a major step toward reducing chemotherapy exposure and accelerating access to immune-based therapies. “Our immune system is ultimately what cures us of cancer, and immune-based therapies will be critical to the future treatment of blood cancers including Hodgkin lymphoma,” Professor Prince said.
The research team plans further studies to reduce chemotherapy even more and bring these treatments to patients in Australia and around the world. For young people facing a Hodgkin lymphoma diagnosis, the trial results offer a powerful reason for optimism. “Clinical trials have the power to change lives,” Professor Prince said. “They provide eligible patients with an opportunity to receive cutting-edge treatments they otherwise would not be able to access.”